Millennium Management LLC bought a new position in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 59,340 shares of the medical research company’s stock, valued at approximately $151,000.

Several other institutional investors also recently bought and sold shares of the company. Stonepine Capital Management LLC grew its position in shares of HTG Molecular Diagnostics by 399.6% during the 4th quarter. Stonepine Capital Management LLC now owns 2,675,889 shares of the medical research company’s stock worth $6,797,000 after buying an additional 2,140,299 shares during the period. Acadian Asset Management LLC grew its position in shares of HTG Molecular Diagnostics by 152.3% during the 4th quarter. Acadian Asset Management LLC now owns 227,407 shares of the medical research company’s stock worth $577,000 after buying an additional 137,276 shares during the period. Geode Capital Management LLC grew its position in shares of HTG Molecular Diagnostics by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 217,965 shares of the medical research company’s stock worth $553,000 after buying an additional 28,472 shares during the period. Requisite Energy Fund I LP acquired a new position in shares of HTG Molecular Diagnostics during the 4th quarter worth about $254,000. Finally, BlackRock Inc. grew its position in shares of HTG Molecular Diagnostics by 16.4% during the 4th quarter. BlackRock Inc. now owns 88,565 shares of the medical research company’s stock worth $225,000 after buying an additional 12,448 shares during the period. Institutional investors own 51.06% of the company’s stock.

Shares of HTGM opened at $2.47 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 6.30 and a quick ratio of 6.05. HTG Molecular Diagnostics Inc has a 52-week low of $2.03 and a 52-week high of $5.46. The company has a market capitalization of $71.31 million, a P/E ratio of -4.12 and a beta of 1.80.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). HTG Molecular Diagnostics had a negative net margin of 80.03% and a negative return on equity of 75.50%. The business had revenue of $3.20 million during the quarter, compared to analyst estimates of $2.77 million. Equities analysts forecast that HTG Molecular Diagnostics Inc will post -0.59 EPS for the current year.

Several brokerages recently issued reports on HTGM. Canaccord Genuity reiterated a “buy” rating and issued a $5.00 price objective on shares of HTG Molecular Diagnostics in a research report on Tuesday. Cantor Fitzgerald set a $6.00 price objective on HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, Zacks Investment Research lowered HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, May 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $6.00.

WARNING: “Millennium Management LLC Buys New Stake in HTG Molecular Diagnostics Inc (HTGM)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.watchlistnews.com/millennium-management-llc-buys-new-stake-in-htg-molecular-diagnostics-inc-htgm/3011738.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.

Further Reading: Gross Domestic Product (GDP)

Want to see what other hedge funds are holding HTGM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HTG Molecular Diagnostics Inc (NASDAQ:HTGM).

Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.